BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com
BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued to investors on Friday. The firm issued a sell rating on the medical technology company's stock.
斯托克新聞網在週五發佈給投資者的一份研究報告中開始報道納斯達克(BIOLASE:BIOL-GET Rating)的股票。該公司對這家醫療技術公司的股票發佈了賣出評級。
Other analysts have also issued research reports about the stock. Benchmark cut their price objective on shares of BIOLASE to $7.00 in a research note on Wednesday, November 16th. Ascendiant Capital Markets cut their price objective on shares of BIOLASE to $14.00 in a research note on Wednesday, November 16th. Finally, Maxim Group dropped their price target on shares of BIOLASE from $10.00 to $5.00 in a research report on Friday, November 11th.
其他分析師也發佈了有關該股的研究報告。11月16日星期三,Benchmark在一份研究報告中將BIOLASE的股價目標下調至7.00美元。在11月16日星期三的一份研究報告中,Ascaldiant Capital Markets將BIOLASE的股票目標價下調至14.00美元。最後,Maxim Group在11月11日星期五的一份研究報告中將BIOLASE的股票目標價從10.00美元下調至5.00美元。
BIOLASE Stock Performance
Biolase股票表現
BIOL opened at $1.02 on Friday. BIOLASE has a 52-week low of $0.93 and a 52-week high of $13.83. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92. The company has a market cap of $7.25 million, a P/E ratio of -0.28 and a beta of 1.45. The firm's 50-day moving average price is $2.01 and its 200-day moving average price is $3.51.
Biol上週五開盤報1.02美元。Biolase的52周低點為0.93美元,52周高位為13.83美元。該公司的速動比率為1.27,流動比率為2.46,債務權益比率為0.92。該公司市值為725萬美元,市盈率為-0.28,貝塔係數為1.45。該公司的50日移動均線價格為2.01美元,200日移動均線價格為3.51美元。
Institutional Trading of BIOLASE
BIOLASE的機構交易
BIOLASE Company Profile
Biolase公司簡介
(Get Rating)
(獲取評級)
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
Biolase公司與其子公司一起,在美國和國際上為牙科醫生及其患者開發、製造、營銷和銷售激光系統。它的牙科激光系統允許牙醫、牙周病醫生、牙髓醫生、口腔外科醫生和其他牙科專家執行一系列微創牙科手術,如美容、修復和複雜的外科應用。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- Best Buy Proves Brick and Mortar is Here to Stay
- MarketBeat: Week in Review 11/21 – 11/25
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- 免費獲取StockNews.com關於BIOLASE的研究報告(Biol)
- 百思買證明磚頭和砂漿將繼續存在
- MarketBeat:回顧一週11/21-11/25
- 三隻CBD股票將主宰一個萌芽行業
- Salesforce裁員,儘管面臨挑戰,但收入強勁
- 機構對ADI的支持仍然很高
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BIOLASE日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對BIOLASE和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。